Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 80% Improvement Relative Risk Recovery 65% Complications 96% Aspirin for COVID-19  Husain et al.  LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? Retrospective 42 patients in Bangladesh Lower mortality (p=0.55) and improved recovery (p=0.4), not sig. c19early.org Husain et al., ResearchGate, October 2020 Favors aspirin Favors control

Beneficial effect of low dose aspirin (Acetyl salicylic acid) in adult Covid-19 patients: a retrospective observational study in Bangladesh

Husain et al., ResearchGate, doi:10.13140/RG.2.2.26038.93762/2
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Aspirin for COVID-19
24th treatment shown to reduce risk in August 2021
 
*, now known with p = 0.000087 from 73 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 42 patients in Bangladesh, 11 treated with aspirin, showing fewer complications with treatment.
risk of death, 80.3% lower, RR 0.20, p = 0.55, treatment 0 of 11 (0.0%), control 3 of 31 (9.7%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no recovery, 64.8% lower, RR 0.35, p = 0.40, treatment 1 of 11 (9.1%), control 8 of 31 (25.8%), NNT 6.0.
complications, 95.8% lower, RR 0.04, p = 0.001, treatment 0 of 11 (0.0%), control 17 of 31 (54.8%), NNT 1.8, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Husain et al., 31 Oct 2020, retrospective, Bangladesh, preprint, 4 authors.
This PaperAspirinAll
Beneficial effect of low dose Aspirin (Acetyl salicylic acid) in adult COVID -19 patients: a retrospective observational study in Bangladesh
Ashaque Husain, Md Abu Sayem, Sm Mostofa Kamal, Monjur E Morshed
doi:10.13140/RG.2.2.26038.93762/2
Background & objectives: Presently Coronavirus disease 2019 is a huge human misery that is almost unstoppable with little remedy on board. The disease is predominantly associated with inflammation and thrombosis. Although aspirin exhibits excellent anti-thrombotic and anti-inflammatory properties, it is yet to be explored in treating Covid-19 patients. In this article we want to bring forth its beneficial effect in Covid-19 case management. Methods: It is a retrospective, non-randomized observational study. Adult Covid-19 patients either diagnosed with RT-PCR (reverse transcriptase polymerized chain reaction), or categorized as probable cases (as per World Health Organization case definition protocol) by medical doctors were enrolled as participants. Data were collected from doctors' office records. Results: Out of 44 participants 42 were eligible (2 children excluded) for the study. Among them 11 participants took low dose aspirin during the disease process. All participants in aspirin group became cured without complication or death (RR 2.2, 95% CI 1.5-3.2, p < 0.001). On the other hand, no aspirin group suffered complications and deaths. Interpretation and conclusions: The study findings revealed that complications were significantly low among aspirin users. It documented that low dose aspirin is beneficial for Covid-19 patients. Further study is warranted with larger sample size.
Discussion The two groups showed significant difference in outcomes. Aspirin intake resulted with no death and a smaller number of complications (tables 3, 4); while aspirin non-users faced deaths or following complications. Myocarditis: It is the inflammation of the myocardium. Pneumonitis: It is the inflammation of the lung tissue that is not caused by infection. Pneumonia: It is the infection of one or both lungs that involves alveoli. Basal fibrosis of lung: It presents with chronic cough, moist rales at lung bases, and basal pulmonary infiltration as revealed by X-ray inspection. Syncopal attack: It is a sudden loss of consciousness and muscle tone due to various reasons. Depressive disorder: It is a mood disorder that causes persistent feeling of sadness. Chronic Bronchitis: It is the chronic inflammation of the bronchus and its branches. Ischemic heart disease: It is a condition when heart muscles get low blood supply due to narrowing of coronary arteries. It may lead to Myocardial infarction that is diagnosed by ECG (Electro Cardiogram), some cardiac bio-markers e.g. Cardiac Troponin, and other invasive tests. That the enrolled cases were contemporary in nature; and that they were treated in similar settings with standard care; might be the strength of the study. But small sized sample statistically limited the strength of the study. But the clinical insight gained from this study may be very useful for Covid-19 case management, especially in low resource settings...
References
Bikdeli, Therapeutic Targets for COVID-19-Associated Thrombosis
Boyle, Di Gangi, Hamid, Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis, Crit Care19
Chen, Janz, Bastarache, Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: a propensity-adjusted analysis, / Crit Care Med
Goodman, s the pharmacological basis of therapeutics / 13 th
Li, Liu, Zhang, SARS-CoV-2 and viral sepsis: observations and hypotheses, Lancet
Looney, Nguyen, Hu, Van Ziffle, Lowell et al., Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury, J Clin Invest
Mistry, Chandratreva, Paul, Lee, A systemic review on the use of Aspirin in the prevention of deep vein thrombosis in major elective lower limb orthopedic surgery: an update from past three years, The Surgery Journal
Panka, De Grooth, Spoelstra-De Man, Looney, Tuinman, Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta-analysis of clinical studies, Shock
Stoppelaar, Van't Veer, Der Poll, The role of platelets in sepsis, Thromb Haemost
Wang, Li, Gu, Wang, Liu, Effect of antiplatelet therapy on acute respiratory distress syndrome and mortality in critically ill patients: a meta-analysis, PLoS One
Wu, Mcgoogan, Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Xing, Zhi, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chinese Center for Disease Control and Prevention
Zarbock, Singbartl, Ley, Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation, J Clin Invest
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit